Naproxen Type of group

An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that COX189 (400 mg od) reduces the risk to develop complicated ulcers as compared to NSAlDs (naproxen 500 mg bid and ibuprofen 800 mg tid), in rheumatoid arthritis and osteoarthritis patients

INTERNATIONAL STUDY, MULTICENTRIC, STRATIFIED, RANDOMIZED, DOUBLE-BLIND, WITH PLACEBO OVERLOAD, IN PARALLEL GROUPS, DURING 52 WEEKS OF GASTROINTESTINAL CLINICAL SECURITY, TO DEMONSTRATE THAT COX189 (400 MG / DAY OD) REDUCES THE RISK OF DISREGARDING COMPLICATED ULCERS COMPARING WITH NSAIDS (NAPROXENO 500 MG, BID AND IBUPROPHENE 800MG.ID) IN PATIENTS WITH OSTEOARTHRITIS, COX STUDY 1189 TARGET PART II